VA study to examine psilocybin for depression and PTSD treatment
The Department of Veterans Affairs has launched a major clinical trial to study whether psilocybin, the active compound in psychedelic mushrooms, can effectively treat depression and PTSD in veterans. The study, called the Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression or PIVOT, will enroll at least 240 veterans across five VA medical centers and run through June 2031. VA Secretary Doug Collins emphasized that the trial represents the department's commitment to exploring new treatment options for veterans whose mental health conditions have not responded to conventional therapies.
This research comes at a critical time for veterans struggling with mental health conditions. Major depressive disorder and PTSD remain among the most common and debilitating conditions affecting veterans, and current treatments including medication and traditional psychotherapy do not work for everyone. The VA currently offers evidence-based treatments at its facilities, but treatment-resistant cases leave many veterans without relief. Recent smaller studies have shown promising results, including research from Ohio State University published in July that found 75% of participants with severe PTSD no longer met clinical criteria for the disorder after receiving synthetic psilocybin combined with psychotherapy.
The PIVOT study will specifically enroll veterans diagnosed with major depressive disorder who have not responded to existing treatments. Some participants will also have PTSD diagnoses, while others will not. Veterans must have difficult-to-treat depression to qualify, meaning they have already tried standard treatment approaches without success. The study will take place at VA medical centers in Birmingham and Tuscaloosa, Alabama; Portland, Oregon; Philadelphia; and Seattle.
Participants in this double-blind, randomized trial will receive either psilocybin or a placebo along with therapeutic support during two sessions spaced one month apart. The VA will use pharmaceutical-grade drugs administered in safe, controlled clinical settings, not recreational substances. Veterans will be evaluated two to four weeks after each session to assess depression levels, side effects, and overall response to treatment, with additional follow-up occurring six months after participation ends. The trial design ensures rigorous scientific standards while prioritizing participant safety.
This research effort follows an executive order signed by President Trump in April directing federal agencies to accelerate review of psychedelic therapies for mental health treatment. As a result, the Department of Health and Human Services and VA signed an agreement to coordinate research, train medical staff for potential future administration of approved psychedelic medications, and collect data to support regulatory decisions. The VA currently has staff involved in 20 clinical trials examining psychedelic treatments including MDMA and LSD, though the FDA rejected an MDMA application for PTSD treatment in 2024 citing the need for additional safety and efficacy research.
For disabled veterans watching this development, the PIVOT study represents potential future treatment options rather than immediate access to care. The VA strongly discourages self-medication and warns veterans not to replace prescribed mental health treatments with psychedelics or other unprescribed substances. Psilocybin remains illegal under federal law outside approved research settings, and using it without medical supervision carries both legal risks and potential health dangers.
Veterans currently struggling with depression or PTSD should continue working with their VA mental health providers and exploring existing evidence-based treatments available at VA facilities. Those interested in participating in clinical trials can ask their VA provider about eligibility for this or other research studies. While promising, psychedelic therapies remain experimental and years away from potential approval, making it essential to pursue proven treatments now rather than waiting for research outcomes that may not materialize until the end of this decade.